Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness

NCT03770403 is registered in ClinicalTrials.gov with argenx as lead sponsor.

NCT NCT03770403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03770403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness
Lead sponsor
argenx
Phase
Phase 3
Overall status
Completed
Start date
March 1, 2019
Completion date
June 30, 2022
Enrollment
151 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

generalized myasthenia gravis